Drawing for CDRD

USPTO serial 87815377

CDRD

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
CARLYLE, SHAUNIA P
Law office
TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with CDRD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael Pampalone

Trisha A. Doré RICHARDS BUELL SUTTON LLP700 - 401 WEST GEORGIA STREETVANCOUVER, BC, V6B5A1CANADA

Goods and services

ClassDescriptionStatusFirst use
042Providing specialized pharmaceutical development and commercialization expertise and infrastructure to identify, validate and advance promising drug discoveries, and to transform such discoveries into commercially viable investment opportunities and into new therapies for patients, namely, (a) providing scientific research information and drug discovery information in the field of pharmaceuticals, (b) providing scientific consulting services in the field of pharmaceutical research, development and commercialization, (c) providing education and training services in the field of pharmaceutical research, development and commercialization, (d) providing pharmaceutical research, inspection, evaluation, testing and development services, (e) providing laboratory research services, (f) providing laboratory and office facilities, apparatus, devices, solutions and instruments, (g) providing technical advice and support services, (h) promoting collaboration within the scientific, research and medical communities to achieve advances in the field of pharmaceuticals, and (i) providing consulting services in the innovation and commercialization of new pharmaceuticals, namely, sourcing investments and partners, analyzing and advancing projects, assisting in commercialization through intellectual property consulting and advice, assisting in executing commercial transactions and corporate structuringACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Aug 25, 2021MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Aug 24, 2021ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Feb 8, 2021GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Feb 8, 2021GNSIINQUIRY TO SUSPENSION E-MAILED—
Feb 8, 2021CNSISUSPENSION INQUIRY WRITTEN—
Jan 29, 2021RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jul 23, 2020RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 21, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 21, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Jan 21, 2020CNSLSUSPENSION LETTER WRITTEN—
Jan 2, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 2, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 2, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 26, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Dec 20, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 20, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 10, 2019GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jul 10, 2019GNSIINQUIRY TO SUSPENSION E-MAILED—
Jul 10, 2019CNSISUSPENSION INQUIRY WRITTEN—
Jul 3, 2019RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 3, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jan 3, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Jan 3, 2019CNSLSUSPENSION LETTER WRITTEN—
Dec 21, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 21, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 21, 2018ALIEASSIGNED TO LIE—
Dec 18, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 18, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 18, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 18, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2018DOCKASSIGNED TO EXAMINER—
Mar 9, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Mar 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 3, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance